双语字幕
Triple Negative Breast Cancer Theratechnologies
三阴性乳腺癌的治疗技术
There have been major advances in the treatment of breast cancer. Unfortunately, the same can not be said for triple-negative breast cancer.
目前，乳腺癌的治疗已经取得了重大进展，然而，三阴性乳腺癌的治疗进展却乏善可陈。
For decades, chemotherapy has been used to treat many forms of cancers, including breast cancer.
数十年来，化疗已被用于乳腺癌等多种癌症的治疗。
However, chemotherapy does not discriminate between healthy and cancerous cells. It attacks both, causing severe side effects.
但是，化疗将无差别的杀伤健康细胞和癌细胞。它同时攻击这两种细胞，导致严重的副作用。
In their quest for more effective and better tolerated cancer treatments, scientists are trying to specially target cancer cells.
为寻求疗效更佳，耐受性更好的癌症治疗方法，科学家们尝试只靶向癌细胞治疗。
Targeting sortilin receptors could be a new avenue to treat many types of cancers.
靶向 sortilin 受体可能是治疗多种癌症的新途径。
Theratechnologies has developed a peptide that can bind to sortilin receptors and to which cytotoxic agents can be attached. The peptide-drug conjugate is internalized and shuttled to lysosomes where the chemotherapeutic agent is released.
Theratechnologies 公司研发了一种可以结合 sortilin 受体，与细胞毒性药物偶联的多肽。多肽偶联药物被吸收，然后转运到溶酶体中，释放化疗剂。
Triple-negative breast cancer is one of the first applications of this targeted technology platform for which we are developing our new conjugate using docetaxel, a commonly used cytotoxic agent.
三阴性乳腺癌等是首批应用这一靶向治疗技术的癌症，我们正在研发使用多西紫杉醇（一种常用的细胞毒性药物）的新偶联药物。
Docetaxel is only one of many cancer agents that can be conjugated to our peptide. Thus opening potential treatment options for many types of cancer.
多西紫杉醇只是众多可以与多肽偶联的癌症治疗药物之一，这为许多癌症提供了潜在的治疗选择。
Our novel conjugate could offer patients more effective and better tolerated cancer treatments.
我们的新型偶联药物为患者提供了疗效和耐受性更好的癌症治疗方案。
Chemotherapy
（图源：太帅图库）
Cytotoxic
Lysosome
（图源：太帅图库）
更多精彩医学双语（中英）视频，请关注公众号↓↓↓
